Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review

Rafferty, Ellen; Duclos, Philippe; Yactayo, Sergio; Schuster, Melanie

doi:10.1016/j.vaccine.2013.09.030

Cited by 43 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…YEL-AVD results from a widespread dissemination of the vaccine virus, closely mimicking wild-type fulminant yellow fever [29]. The case-fatality rate has been estimated at ~65% [29] and although sex and advanced age appear to be significant risk factors [68,80,81], a substantial number of cases have also been observed in healthy young adults, as well as children [81]. Following the initial description of YEL-AVD, increased monitoring has led to a growing number of case reports across multiple continents [72,81], with retrospective analysis dating cases to as early as the 1970s [82].…”

Section: Yellow Fever Vaccine-associated Viscerotropic Disease (Yementioning

confidence: 99%

“…While precise measurements of the incidence of YEL-AVD in large populations are limited by the lack of adequate prospective data, several retrospective reviews have addressed the rate of this life-threatening condition [62,65,68,80,81,83]. The CDC identified a total of 72 cases from 437 million doses administered from 1990–2010, for an estimated rate of 0.16 cases of YEL-AVD per million doses administered [11].…”

Section: Yellow Fever Vaccine-associated Viscerotropic Disease (Yementioning

confidence: 99%

See 1 more Smart Citation

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Amanna

Slifka

2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas Covered We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert Commentary Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

show abstract

Section: Yellow Fever Vaccine-associated Viscerotropic Disease (Yementioning

confidence: 99%

Section: Yellow Fever Vaccine-associated Viscerotropic Disease (Yementioning

confidence: 99%

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Amanna

Slifka

2016

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Including 12 probable cases, the rate increased to 0.6/100,000 doses, 7/12 were in people >50 years old (but risk per age group is not provided), and 9/12 were male. Rafferty et al 14 in a systematic review, found that 2 out of 5 studies showed significantly higher rate of YEL-AVD among the elderly population, and considered that this population may be at increased risk of YEL-AVD, but the evidence was limited. Seligman showed suggestive evidence of increased risk of YEL-AVD in young women without known immunodeficiency.…”

Section: Vaccine-associated Viscerotropicmentioning

confidence: 99%

Serious adverse events associated with yellow fever vaccine

Martins

Leal²,

Homma³

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The vaccine has also been used as a backbone to develop other flavivirus vaccines (Bredenbeek et al, 2006; Guy et al, 2011; Guy et al, 2010; Ishikawa et al, 2014; Stoyanov et al, 2010). Active case-analyses in several countries found only rare 17D vaccine-associated adverse effects including YF vaccine-associated neurologic disease (YEL-AND) and viscerotropic disease (YEL-AVD), as well as allergic reactions (Breugelmans et al, 2013; Ishikawa et al, 2014; Rafferty et al, 2013). Some adverse events appear to be associated with host factors rather than with the vaccine (Barban et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice

et al. 2014

View full text Add to dashboard Cite

Yellow fever (YF) causes an acute hemorrhagic fever disease in tropical Africa and Latin America. To develop a novel experimental YF vaccine, we applied iDNA infectious clone technology. The iDNA represents plasmid that encodes the full-length RNA genome of 17D vaccine downstream from a cytomegalovirus (CMV) promoter. The vaccine was designed to transcribe the full-length viral RNA and to launch 17D vaccine virus in vitro and in vivo. Transfection with 10ng of iDNA plasmid was sufficient to start replication of vaccine virus in vitro. Safety of the parental 17D and iDNA-derived 17D viruses was confirmed in AG129 mice deficient in receptors for IFN-α/β/γ. Finally, direct vaccination of BALB/c mice with a single 20µg dose of iDNA plasmid resulted in seroconversion and elicitation of virus-specific neutralizing antibodies in animals. We conclude that iDNA immunization approach combines characteristics of DNA and attenuated vaccines and represents a promising vaccination strategy for YF.

show abstract

Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review

Cited by 43 publications

References 29 publications

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Serious adverse events associated with yellow fever vaccine

Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice

Contact Info

Product

Resources

About